AAAAAA

   
Results: 1-10 |
Results: 10
Isolation of plasma kallikrein by high efficiency affinity chromatography and its characterization
Authors: Tada, M Tsuda, Y Wanaka, K Hijikata-Okunomiya, A Horie, N Okamoto, U Okamoto, S Okada, Y
Citation: M. Tada et al., Isolation of plasma kallikrein by high efficiency affinity chromatography and its characterization, BIOL PHAR B, 24(5), 2001, pp. 520-524
Binding diversity of a noncovalent-type low-molecular-weight serine protease inhibitor and function of a catalytic water molecule: X-ray crystal structure of PKSI-527-inhibited trypsin
Authors: Tomoo, K Satoh, K Tsuda, Y Wanaka, K Okamoto, S Hijikata-Okunomiya, A Okada, Y Ishida, T
Citation: K. Tomoo et al., Binding diversity of a noncovalent-type low-molecular-weight serine protease inhibitor and function of a catalytic water molecule: X-ray crystal structure of PKSI-527-inhibited trypsin, J BIOCHEM, 129(3), 2001, pp. 455-460
Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors
Authors: Tsuda, Y Tada, M Wanaka, K Okamoto, U Hijikata-Okunomiya, A Okamoto, S Okada, Y
Citation: Y. Tsuda et al., Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors, CHEM PHARM, 49(11), 2001, pp. 1457-1463
Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (Melanoma) and HT29 cell lines
Authors: Okada, Y Tsuda, Y Wanaka, K Tada, M Okamoto, U Okamoto, S Hijikata-Okunomiya, A Bokonyi, G Szende, B Keri, G
Citation: Y. Okada et al., Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (Melanoma) and HT29 cell lines, BIOORG MED, 10(19), 2000, pp. 2217-2221
Effects of argatroban on thrombin-induced events in cultured vascular smooth muscle cells
Authors: Hijikata-Okunomiya, A Nakaya, Y Inoue, N Takahashi, A Taniguchi, T Wanaka, K Tsuda, Y Okada, Y Ishikawa, Y
Citation: A. Hijikata-okunomiya et al., Effects of argatroban on thrombin-induced events in cultured vascular smooth muscle cells, THROMB RES, 97(4), 2000, pp. 257-262
Development of plasmin-selective inhibitors and studies of their structure-activity relationship
Authors: Okada, Y Matsumoto, Y Tsuda, Y Tada, M Wanaka, K Hijikata-Okunomiya, A Okamoto, S
Citation: Y. Okada et al., Development of plasmin-selective inhibitors and studies of their structure-activity relationship, CHEM PHARM, 48(2), 2000, pp. 184-193
Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship
Authors: Okada, Y Tsuda, Y Tada, M Wanaka, K Okamoto, U Hijikata-Okunomiya, A Okamoto, S
Citation: Y. Okada et al., Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship, CHEM PHARM, 48(12), 2000, pp. 1964-1972
Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: The importance of the peptide backbone
Authors: Fukumizu, A Tsuda, Y Wanaka, K Tada, M Okamoto, S Hijikata-Okunomiya, A Okada, Y
Citation: A. Fukumizu et al., Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: The importance of the peptide backbone, CHEM PHARM, 47(8), 1999, pp. 1141-1144
Development of plasma kallikrein selective inhibitors
Authors: Okada, Y Tsuda, Y Tada, M Wanaka, K Hijikata-Okunomiya, A Okamoto, U Okamoto, S
Citation: Y. Okada et al., Development of plasma kallikrein selective inhibitors, BIOPOLYMERS, 51(1), 1999, pp. 41-50
Enzyme-controlling medicines: Introduction
Authors: Okamoto, S Hijikata-Okunomiya, A Wanaka, K Okada, Y Okamoto, U
Citation: S. Okamoto et al., Enzyme-controlling medicines: Introduction, SEM THROMB, 23(6), 1997, pp. 493-501
Risultati: 1-10 |